These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Recombinant activated factor VII for intractable bleeding post splenectomy in a patient with myeloproliferative disorder.
    Author: El Kinge AR, Mahfouz RA, Shamseddine AI, Taher AT.
    Journal: Blood Coagul Fibrinolysis; 2007 Sep; 18(6):577-9. PubMed ID: 17762536.
    Abstract:
    Recombinant activated factor VII has been Food and Drug Administration approved to treat hemorrhages in hemophiliac patients with inhibitors and in acquired hemophilia patients. Recombinant activated factor VII use has also been considered for the management of uncontrolled bleeding in a number of congenital and acquired hemostatic abnormalities. The myeloproliferative disorders are a group of clonal hematologic diseases where, frequently, abnormal platelet function is considered a hallmark. This is the first case report addressing the clinical benefit of off-label use of recombinant activated factor VII in an attempt to control intractable bleeding in a patient with a myeloproliferative disorder after splenectomy.
    [Abstract] [Full Text] [Related] [New Search]